Last reviewed · How we verify
Aspirin + Ticagrelor
Aspirin and ticagrelor work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.
Aspirin and ticagrelor work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways. Used for Acute coronary syndrome (ACS) for secondary prevention of thrombotic events, Stable coronary artery disease for secondary prevention.
At a glance
| Generic name | Aspirin + Ticagrelor |
|---|---|
| Also known as | Brilinta, acetylsalicylic acid [ASA] + Brillinta |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Dual antiplatelet agent |
| Target | COX-1 (aspirin); P2Y12 receptor (ticagrelor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Ticagrelor is a P2Y12 receptor antagonist that reversibly blocks ADP-mediated platelet aggregation. Together, they provide complementary antiplatelet effects to reduce thrombotic events.
Approved indications
- Acute coronary syndrome (ACS) for secondary prevention of thrombotic events
- Stable coronary artery disease for secondary prevention
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |